Exclusive: Global trial finds treatment with amivantamab and lazertinib halts progression for average of 23.7 months.
‘Amazing’ trial shows drug combination stops lung cancer advancing for longer
Posted in biotech/medical
Posted in biotech/medical
Exclusive: Global trial finds treatment with amivantamab and lazertinib halts progression for average of 23.7 months.